Wells Fargo & Company began coverage on shares of Ventyx Biosciences (NASDAQ:VTYX – Get Rating) in a report published on Monday morning, Marketbeat.com reports. The brokerage issued an overweight rating and a $77.00 price objective on the stock. A number of other research analysts have also recently issued reports on the company. Evercore ISI lifted […]
Wells Fargo & Company assumed coverage on shares of Ventyx Biosciences (NASDAQ:VTYX – Get Rating) in a research note published on Monday morning, Marketbeat Ratings reports. The firm issued an overweight rating and a $77.00 target price on the stock. Other equities analysts also recently issued reports about the company. The Goldman Sachs Group started […]
Ventyx Biosciences (NASDAQ:VTYX – Get Rating) had its target price lifted by Oppenheimer from $60.00 to $65.00 in a report issued on Monday morning, The Fly reports. Oppenheimer also issued estimates for Ventyx Biosciences’ FY2026 earnings at ($2.75) EPS and FY2027 earnings at ($2.89) EPS. Other equities analysts have also recently issued reports about the […]
Should You Buy or Sell Ventyx Biosciences Stock? Get The Latest VTYX Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
SG Americas Securities LLC acquired a new position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Rating) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 21,415 shares of the company’s stock, valued at approximately $202,000. SG Americas Securities LLC owned approximately 0.06% […]